Advertisement

Topics

Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC

15:00 EDT 16 Apr 2018 | Drugs.com

MONDAY, April 16, 2018 -- For metastatic non-small-cell lung cancer (NSCLC), the addition of pembrolizumab to standard chemotherapy is beneficial; and nivolumab plus ipilimumab is associated with better survival than chemotherapy for NSCLC with high...

Original Article: Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC

NEXT ARTICLE

More From BioPortfolio on "Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...